Trial Profile
Comparison of Pharmacokinetics of and Effect on Systemic Vascular Endothelial Growth Factor (VEGF) Levels Over Time of Intravitreal Ranibizumab and Bevacizumab and Aflibercept in Age Related Macular Degeneration Patients
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 10 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
- 10 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
- 10 Aug 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.